ABOS vs. TSHA, ATXS, ATYR, ATAI, CMPS, GLUE, ARCT, TKNO, SEPN, and ENGN
Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), COMPASS Pathways (CMPS), Monte Rosa Therapeutics (GLUE), Arcturus Therapeutics (ARCT), Alpha Teknova (TKNO), Septerna (SEPN), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.
Acumen Pharmaceuticals vs.
Taysha Gene Therapies (NASDAQ:TSHA) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
Acumen Pharmaceuticals has lower revenue, but higher earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Acumen Pharmaceuticals has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -229.67%. Acumen Pharmaceuticals' return on equity of -32.99% beat Taysha Gene Therapies' return on equity.
Taysha Gene Therapies received 81 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. Likewise, 77.70% of users gave Taysha Gene Therapies an outperform vote while only 72.97% of users gave Acumen Pharmaceuticals an outperform vote.
Taysha Gene Therapies presently has a consensus price target of $6.63, indicating a potential upside of 417.58%. Acumen Pharmaceuticals has a consensus price target of $7.33, indicating a potential upside of 566.67%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Taysha Gene Therapies.
77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Taysha Gene Therapies has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500.
In the previous week, Taysha Gene Therapies had 3 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.68 beat Taysha Gene Therapies' score of 0.70 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.
Summary
Taysha Gene Therapies and Acumen Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Acumen Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acumen Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ABOS) was last updated on 4/15/2025 by MarketBeat.com Staff
